


HIV-1 inhibitor-52

Cat. No.:	HY-152157
CAS No.:	1818868-23-3
Molecular Formula:	C ₄₆ H ₇₂ FNO ₅ S
Molecular Weight:	770.13
Target:	HIV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	HIV-1 inhibitor-52 is a potent broad-spectrum HIV-1 activity inhibitor with EC ₅₀ s of 1.6 nM-6.4 nM for WT HIV-1, HIV-1 V370A, HIV-1 ΔV370, HIV-1 V362I/V370A, HIV-1 T332S/V362I/prR41G, HIV-1 A326T/V362I/V370A, HIV-1 R361K/V362I/L363M ^[1] .			
IC₅₀ & Target	HIV-1 (WT) 1.6 nM (EC50)	HIV-1 V370A 3.0 nM (EC50)	HIV-1 ΔV370 5.1 nM (EC50)	HIV-1 V362I/V370A 2.0 nM (EC50)
	HIV-1 T332S/V362I/prR41G 6.4 nM (EC50)	HIV-1 A326T/V362I/V370A 4.3 nM (EC50)	HIV-1 R361K/V362I/L363M 4.5 nM (EC50)	
In Vivo	HIV-1 inhibitor-52 (compound 26; 1 mg/kg; IV) has a T _{1/2} of 4.2 hours, a CL of 3.5 mL/min·kg, and a V _{SS} of 0.8 L/kg for rats ^[1] . HIV-1 inhibitor-52 (5 mg/kg; po) has a C _{max} of 0.83 μM and an AUC of 8.11 μM·h for rats ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
	Animal Model:	Male sprague-dawley rats ^[1]		
	Dosage:	1 mg/kg		
	Administration:	IV		
	Result:	Had a T _{1/2} of 4.2 hours, a CL of 3.5 mL/min·kg, and a V _{SS} of 0.8 L/kg for rats.		

REFERENCES

[1]. Richard A Hartz, et al. Synthesis, Structure-Activity Relationships, and In Vivo Evaluation of Novel C-17 Amine Derivatives Based on GSK3640254 as HIV-1 Maturation Inhibitors with Broad Spectrum Activity. J Med Chem. 2022 Dec 8;65(23):15935-15966.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA